Year: 2020

— Received $98.4 million in aggregate gross proceeds in October from initial public offering —— Initiated Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the treatment of solid tumors —— Announced clinical trial collaboration with Merck to evaluate combination of ONCR-177 with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1 clinical trial —CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today reported third quarter 2020 financial results and highlighted recent achievements and developments.“We’ve made significant strides thus far in 2020 advancing our mission to realize the full promise of viral immunotherapy for cancer patients,...

PDF Available: http://ml.globenewswire.com/Resource/Download/8e0089e5-47ed-4362-8ef9-cb82d2b94108CALGARY, Alberta, Nov. 11, 2020 (GLOBE NEWSWIRE) — (PIPE – TSX-V) Pipestone Energy Corp. (“Pipestone Energy” or the “Company”) is pleased to report its Q3 2020 financial and operational results, as well as provide an update to its development program and corporate guidance for 2021.“I am extremely proud of the efforts of our team as we continue to safely navigate the global pandemic and its impact on oil prices,” said Paul Wanklyn, President and CEO. “The recently completed financing was an important step in enabling Pipestone Energy to resume its growth in production and cashflow in order to achieve critical mass. We have modified our capital spending profile to reflect some of the continued challenges our industry faces but we retain...

Third Quarter and First Nine Months of 2020 Revenues were $35.3 million and $101.7 million Respectively, a 7% Increase Compared to Both 2019 Periods; Company Reiterates Full-Year 2020 Total Revenue Guidance of $132 Million to $137 MillionNet Income for Third Quarter and First Nine Months of 2020 was $6.8 million and $15.5 million, Respectively, Compared to $5.8 Million and $16.9 Million in 2019, RespectivelyContinued to Advance Development of a Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) Through a $3.4 million Supply Agreement with the Israeli Ministry of Health and Positive Interim Results from an Ongoing Phase 1/2 Clinical StudyExploring Strategic Business Development Initiatives Focused on Utilizing Kamada’s Core Plasma-Derived Pharmaceuticals Development, Manufacturing...

MONTREAL, Nov. 11, 2020 (GLOBE NEWSWIRE) — Nuvei Corporation (“Nuvei” or the “Company”) (TSX: NVEI and NVEI.U), the global payment technology partner of thriving brands, today reported financial results for its third quarter of 2020.“I am incredibly proud of all that we accomplished in the third quarter, as we embarked on our journey as a publicly-traded company. We believe our performance, which included total volume* of $11.5 billion along with strong revenue growth, is a testament to the strength of our technology, business model and focus on high growth verticals,” said Philip Fayer, Nuvei’s chairman and CEO. “Furthermore, we made significant progress executing our growth strategy, broadening our capabilities and footprint, as well as winning many notable clients. We earned regulatory approval in the states of Indiana and Colorado...

MONTRÉAL, 11 nov. 2020 (GLOBE NEWSWIRE) — Corporation Nuvei (« Nuvei » ou la « Société ») (TSX : NVEI et NVEI.U), le partenaire technologique de paiement des marques prospères, a communiqué aujourd’hui ses résultats financiers pour le troisième trimestre de 2020.« Je suis extrêmement fier de tout ce que nous avons accompli au cours du troisième trimestre, alors que nous nous sommes lancés dans notre aventure en tant que société ouverte. Nous estimons que notre rendement, qui s’est traduit par un volume total* de 11,5 G $ et une forte croissance des produits des activités ordinaires, témoigne de la force de notre technologie, de notre modèle d’affaires et de l’accent que nous plaçons sur les secteurs verticaux à forte croissance », a affirmé Philip Fayer, président du conseil et chef de la direction de Nuvei....